Balanced news tone
News Sentiment
4502 sentiment intelligence
Takeda Pharmaceutical Company Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
87/100 classification confidence.
directly relevant articles
high-authority source matches
-2.4% over one week, +2.9% over four weeks, trend inactive, and materially above fair value.
TAK News Today | Why did Takeda Pharmaceutical stock go down today? $TAK
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
TAK News Today | Why did Takeda Pharmaceutical stock go down today? $TAK
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Aug 2026 07:00
- Source
- MarketBeat
Takeda (TSE:4502) Stock Struggles To Convert Revenue Growth Into Lasting Profit
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 31 Jul 2026 11:46
- Source
- simplywall.st
Can Takeda Pharmaceutical (TSE:4502) Trade At A Discount On New Phase 3 Psoriasis Data?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jul 2026 13:27
- Source
- simplywall.st
Takeda (TSE:4502) Stock Looks Below Fair Value While Broader Checks Stay Mixed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jul 2026 23:12
- Source
- Yahoo! Finance Canada
How New Phase 3 Psoriasis Data For Zasocitinib At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Story
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jul 2026 07:00
- Source
- Market source
The Bull Case For Takeda Pharmaceutical (TSE:4502) Could Change Following New Zasocitinib Phase 3 Psoriasis Data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jul 2026 14:27
- Source
- simplywall.st
TAK|Takeda Pharmaceutical Co Ltd|Price:17.090|Chg%:-0.155
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jul 2026 13:40
- Source
- TradingKey
Takeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervalued
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jul 2026 10:30
- Source
- simplywall.st
Takeda (TAK) completes long-term incentive share issuance and treasury share disposal
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 07:00
- Source
- Stock Titan
Takeda Pharmaceutical (TSE:4502) Is Up 5.3% After New Insilico AI Drug Discovery Deal - Has The Bull Case Changed?
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Jul 2026 07:00
- Source
- simplywall.st
Takeda (TSE:4502) Stock Still Looks Slightly Undervalued Overall
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 07:00
- Source
- simplywall.st
Takeda’s New AI Drug Discovery Deal With Insilico Might Change The Case For Investing In Takeda Pharmaceutical (TSE:4502)
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Jul 2026 07:00
- Source
- Market source
Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Market source
Takeda sees return to growth within three years, new CEO says
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- The Japan Times
Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- GuruFocus
MS-Japan Index Earning Revision (May): Mitsubishi, Takeda Pharmaceutical, Mitsubishi UFJ Financial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 May 2026 07:00
- Source
- Smartkarma
Takeda Pharmaceutical (TSE:4502) Valuation Check As Short Term Weakness Meets Longer Term Returns
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Market source
Takeda (TAK) plans FY2025 IFRS earnings revision after AMITIZA antitrust verdict
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- Stock Titan
Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Morningstar
Takeda Pharmaceutical : Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- marketscreener.com
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 May 2026 07:00
- Source
- Market source
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- Market source
A Look At Takeda Pharmaceutical (TSE:4502) Valuation After Mixed Pipeline News On DNL593 And Zasocitinib
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Apr 2026 07:00
- Source
- Market source
Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 25 Mar 2026 07:00
- Source
- TradingView
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 31 Jan 2026 08:00
- Source
- Market source
Assessing Takeda Pharmaceutical (TSE:4502) After Recent Pipeline Progress And Share Price Moves
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- Market source
Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Dec 2025 08:00
- Source
- Seeking Alpha
China's Innovent signs cancer therapy deal with Japan's Takeda
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 21 Oct 2025 07:00
- Source
- Reuters
Japan's Takeda weighs India for global trials to speed up drug launches
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Aug 2025 07:00
- Source
- Reuters